Home / Leaderboard / Gilead Sciences, Inc.
Gilead Sciences, Inc.
Daniel O'Day · Venture Capital · Venture
Gilead Sciences, Inc. is a leading American biopharmaceutical company founded in 1987 and headquartered in Foster City, California. While primarily recognized for its research and development of innovative therapies in HIV, viral hepatitis, and oncology, the company maintains a significant institutional investment presence through strategic equity holdings in its biotechnology partners. Gilead utilizes its corporate development arm to deploy capital into emerging life sciences firms, fostering long-term collaborations that drive its clinical pipeline. By filing regular 13F reports with the SEC, the company discloses a multi-billion dollar portfolio of strategic stakes in public biotechnology companies, reflecting its commitment to advancing medical breakthroughs through both internal innovation and external investment.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +36.5% |
| YTD return | +7.7% |
| Sharpe ratio | 3.84 |
| Win rate | 67% |
| AUM | $1.9B |
| Inception | Oct 1, 2025 |
| Updated | Sep 18, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.9B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.gilead.com |
Current Holdings
Updated on Sep 18, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| RCUS | Arcus Biosciences Inc | 46.0% | +22.0% |
| LKFT | LKFT | 45.3% | +5.1% |
| ASMB | Assembly Biosciences Inc | 6.8% | -4.6% |
| KYTX | Kyverna Therapeutics, Inc. Common Stock | 1.6% | -6.5% |
| XLO | Xilio Development Inc | 0.3% | +3.4% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 10, 2026 | SELL | XLO | 0.4% → 0.3% |
| Aug 10, 2026 | BUY | LKFT | 30.6% → 45.3% |
| Aug 10, 2026 | SELL | ASMB | 8.4% → 6.8% |
| Aug 10, 2026 | SELL | KYTX | 2.2% → 1.6% |
| Aug 10, 2026 | SELL | RCUS | 58.4% → 46.0% |
Investment Style Analysis
Gilead Sciences, Inc. is widely recognized for employing a Venture strategy. As of Sep 18, 2026, the firm oversees approximately $1.9B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Other sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 10, Gilead Sciences, Inc. made a significant move by reducing the position in XLO. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Gilead's investment philosophy focuses on strategic capital allocation to accelerate transformative science in areas of high unmet medical need. The company prioritizes minority equity stakes and structured partnerships with biotechnology firms specializing in oncology, immunology, and viral diseases. By identifying and supporting early-to-mid-stage medical innovation, Gilead aims to integrate external scientific advancements into its broader commercial ecosystem, ensuring a sustainable pipeline of next-generation therapies while participating in the value creation of the global healthcare startup landscape.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Gilead Sciences, Inc..
Similar Investment Style
Based on Venture.
- Accel Partners — Jim Swartz · 3M +18.1%
- Deer Management Co. LLC — Robert P. Goodman · 3M -8.6%
- New Enterprise Associates, Inc. — Scott Sandell · 3M +6.9%
- Nextech Invest Ltd. — Alfred Scheidegger · 3M +9.7%
Frequently asked questions
How is the simulated portfolio for Gilead Sciences, Inc. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Gilead Sciences, Inc.'s largest holding?
As of the latest filing, Gilead Sciences, Inc.'s top position is Arcus Biosciences Inc (RCUS), representing 46.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Gilead Sciences, Inc.'s historical performance and risk profile?
Our simulation indicates a total return of +36.5% with a win rate of 67%. Notably, the portfolio maintains a Sharpe Ratio of 3.84, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Gilead Sciences, Inc. primarily invest in?
Gilead Sciences, Inc. has a strong preference for the Biotechnology sector, which makes up 54.7% of their disclosed assets. The portfolio also has exposure to Other, indicating a specific thematic focus.
Is Gilead Sciences, Inc.'s portfolio concentrated or diversified?
Gilead Sciences, Inc. runs a highly concentrated portfolio with 5 disclosed positions. The top 3 holdings alone account for 98.1% of the total portfolio weight, suggesting a strategy that favors deep research into a few key names.
How has Gilead Sciences, Inc. performed in 2026?
Our AI-simulated model portfolio for Gilead Sciences, Inc. tracks a Year-to-Date (YTD) return of +7.7%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Daniel O'Day manage Gilead Sciences, Inc. directly?
Yes, Daniel O'Day serves as the key portfolio manager for Gilead Sciences, Inc., overseeing the investment strategy and final capital allocation decisions.